Nuvectis Pharma director gets 35,000 share grant

Sanchez Juan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Sanchez Juan reported acquisition or exercise transactions in this Form 4 filing.

Nuvectis Pharma director Juan Sanchez received a grant of 35,000 shares of restricted common stock at no cost. The award will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the Board of Directors.

After this grant, Sanchez holds 113,380 common shares directly and 415 shares indirectly as custodian for his son. The filing also notes that his current holdings include 230 restricted shares that had been inadvertently omitted from his earlier Form 3.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 2 txns

Insider Sanchez Juan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	35,000	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 113,380 shares (Direct); Common Stock — 415 shares (Indirect, As custodian for son)

Footnotes (2)

1. F1. The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Dr. Sanchez's continued service on the Company's Board of Directors on such dates.
2. F2. Includes 230 shares of restricted common stock that were inadvertently omitted from the initial holdings on Dr Sanchez's Form 3, filed on October 31, 2025.

Key Figures

Restricted stock grant: 35,000 shares Grant price: $0.0000 per share Direct holdings after grant: 113,380 shares +3 more

6 metrics

Restricted stock grant 35,000 shares Restricted common stock awarded to director Juan Sanchez

Grant price $0.0000 per share Reported price for restricted stock grant

Direct holdings after grant 113,380 shares Common stock directly owned by Juan Sanchez after transaction

Indirect holdings 415 shares Common stock held as custodian for son

Previously omitted restricted shares 230 shares Restricted common stock omitted from initial Form 3, now included

Vesting period 3 years Equal annual installments beginning on first anniversary of grant

Key Terms

restricted common stock, vest, Board of Directors, Form 3, +1 more

5 terms

restricted common stock financial

"The 35,000 shares of restricted common stock will vest in equal annual installments"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

vest financial

"will vest in equal annual installments over three years beginning on the first anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Board of Directors financial

"subject to Dr. Sanchez's continued service on the Company's Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Form 3 regulatory

"that were inadvertently omitted from the initial holdings on Dr Sanchez's Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

indirect ownership financial

"direct_or_indirect": "I", "nature_of_ownership": "As custodian for son""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuvectis Pharma (NVCT) director Juan Sanchez report in this Form 4?

Juan Sanchez reported receiving 35,000 shares of restricted common stock as a grant. The award was given at no cost and increases his direct holdings to 113,380 shares, plus 415 shares held indirectly as custodian for his son.

How do the 35,000 restricted shares for NVCT’s Juan Sanchez vest?

The 35,000 restricted shares vest in three equal annual installments. Vesting begins on the first anniversary of the grant date and is conditioned on Sanchez’s continued service on Nuvectis Pharma’s Board of Directors on each vesting date.

What are Juan Sanchez’s total reported NVCT shareholdings after this grant?

After the grant, Sanchez holds 113,380 Nuvectis Pharma common shares directly and 415 shares indirectly as custodian for his son. The filing also confirms that his current total includes 230 restricted shares previously omitted from his Form 3.

Is the 35,000-share NVCT grant to Juan Sanchez a market purchase or sale?

The 35,000 shares are a grant of restricted common stock, not a market trade. The transaction code "A" identifies it as a grant, award, or other acquisition, with a reported price of $0.0000 per share rather than an open-market purchase.

What clarification does the NVCT Form 4 give about Juan Sanchez’s earlier Form 3?

The Form 4 notes that 230 restricted common shares were inadvertently omitted from Sanchez’s initial Form 3. Those 230 shares are now included in his reported current holdings, providing a more accurate picture of his ownership position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanchez Juan

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.,

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NEW JERSEY 07024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		35,000(1)	A	$0	113,380(2)	D
Common Stock								415	I	As custodian for son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Dr. Sanchez's continued service on the Company's Board of Directors on such dates.

2. Includes 230 shares of restricted common stock that were inadvertently omitted from the initial holdings on Dr Sanchez's Form 3, filed on October 31, 2025.

	/s/ Juan Sanchez	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)